985TiPTRIAL IN PROGRESS: PHASE 3 RANDOMIZED STUDY OF INVESTIGATIONAL DRUG ALISERTIB (MLN8237) VS INVESTIGATOR'S CHOICE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (REL/REF) PERIPHERAL T-CELL LYMPHOMA (PTCL): THE LUMIERE TRIAL

in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) – the Lumiere trial Muhit Ozcan,1 Andrei Shustov,2 Hua Liu,3 Xiaofei Zhou,3 Claudio Dansky Ullmann,3 Virginia Kelly,3 E. Jane Leonard,3 Owen O’Connor4 1Ankara University School of Medicine, Ankara, Turkey; 2University of Washington Medical Center, Seattle, WA, USA; 3Takeda Pharmaceuticals International Co., Cambridge, MA, USA; 4Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA